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Abstract
Setting: To reduce the risk of tuberculosis (TB) among individuals with HIV infection, WHO 
recommends at least six months of isoniazid preventive therapy (IPT). Completion of IPT remains 
a major challenge in resource-limited settings.
Objective: We evaluated predictors of IPT completion in individuals newly diagnosed with HIV.
Design: Predictors of IPT completion among adults newly diagnosed with HIV in rural Malawi 
were evaluated using a multilevel logistic regression model.
Results: 974 participants screened negative for active TB and were started on IPT, 732 (75%) of 
whom completed treatment. Only 1 IPT eligible individual refused treatment. Participants <25 
years (compared to those >45 years, aOR: 0.33, 95% CI: 0.18–0.60) and men (compared to non-
pregnant women, aOR: 0.57, 95% CI: 0.37–0.88) had lower odds of IPT completion.
Conclusion: IPT provision at the time of an initial HIV diagnosis was highly acceptable in rural 
Malawi; three-quarters of those who initiated IPT successfully completed therapy. We observed 
lower odds of completion among men and female participants younger than 25 years old. 
Additional efforts may be needed to ensure IPT completion for men and young women who have 
been recently diagnosed with HIV.
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INTRODUCTION:
Tuberculosis (TB) remains a leading cause of death among individuals living with HIV 
worldwide 1. While antiretroviral therapy (ART) reduces the risk of developing TB disease 
among HIV-infected individuals, the risk of TB activation is still higher among those with 
HIV than amongst their HIV-uninfected counterparts, especially in the first six months of 
ART 2. Treatment with isoniazid preventive therapy (IPT) has been shown to reduce the risk 
of TB disease in those with HIV above and beyond the effects of ART alone, and has also 
demonstrated a synergistic effect when administered concomitantly with ART 3,4. Recent 
evidence suggests that IPT may have a mortality benefit in this population as well 5,6.
Despite longstanding recommendations from the World Health Organization (WHO) that ≥6 
months of IPT should be offered to all HIV-infected individuals in whom active TB disease 
is not suspected, global IPT coverage remains low 7. It is estimated that only 25% of the 
IPT-eligible individuals in HIV care are currently receiving IPT 8, and those who do initiate 
face barriers to treatment completion, including stigma, fear of side effects, poor 
relationships with healthcare providers, transport costs, and the challenge of taking 
medication in the absence of symptoms 9,10.
Providing IPT soon after an HIV diagnosis targets those at highest risk of TB disease in the 
period before and immediately after ART initiation (and who therefore stand to benefit the 
most from IPT) and is achievable in routine clinical settings. Identifying those individuals at 
greatest risk of non-adherence could inform targeted strategies to provide additional 
adherence support, which in turn may boost completion rates and reduce incident TB. While 
a small number of studies have evaluated predictors of IPT adherence in South Africa 9,11,12, 
few studies have been done in low-income settings. In an effort to inform strategies to 
improve IPT adherence, we sought to identify predictors of IPT completion under 
operational conditions among a cohort of recently diagnosed HIV patients in Malawi, a high 
TB/HIV burden country where IPT scale-up has achieved relatively higher coverage 13.
STUDY POPULATION AND METHODS:
Study Design
This analysis is nested in a larger randomized clinical trial of TB diagnosis among adults 
newly diagnosed with HIV in rural Malawi (CHEPETSA, clinicaltrials.gov 
#NCT01450085). Twelve clinics were randomized in three phases to one of two TB 
screening algorithms:symptom screening plus sputum smear microscopy, and symptom 
screening plus Xpert MTB/RIF (Cepheid, Inc.; Sunnyvale, CA). Individuals in both arms for 
whom active TB disease was excluded were prescribed six months of IPT. Data for this 
analysis were limited to participants recruited and started on IPT on or before July 1, 2014 
from eight clinics participating in the first two phases of the trial.
Participants were eligible for the study if they were ≥18 years of age and were not taking 
IPT, on TB treatment, or receiving antiretroviral therapy (ART) in the study clinic at 
enrollment. Participants were not eligible to participate if they were unable to speak English 
or Chichewa, had hearing impairments, were a prisoner, or were unwilling/unable to give 
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informed consent. All participants underwent TB symptom screening, and those who 
reported ≥1TB symptoms received same-day microbiological testing with either LED 
fluorescence microscopy or Xpert MTB/RIF.
All participants in whom active TB disease had been excluded were screened for IPT 
eligibility 14. Symptomatic participants who tested negative for TB disease became eligible 
for IPT if/when their symptoms resolved. Participants who had known liver disease, reported 
excessive alcohol consumption (>2 times per week, or 3+ drinks per drinking day), or had a 
history of epilepsy, kidney failure, or severe peripheral neuropathy were considered 
ineligible; all others were offered IPT. Eligible participants were prescribed six months of 
IPT, dispensed in monthly or semi-monthly intervals during routine clinic visits. The number 
of pills dispensed at each visit was documented in the participant’s study file and used to 
track adherence. ART was initiated after enrollment per the Malawian Ministry of Health’s 
contemporary HIV guidelines 14; eligibility for ART included WHO Stage 3 or 4 disease, 
CD4+ T-cell count <350 cells/mm3, or pregnancy/breastfeeding.
Study Procedures
Study participants who were eligible for IPT were offered 300 mg of isoniazid daily, as well 
as 25 mg of pyridoxine daily, for six months. Up to 180 doses of IPT were dispensed during 
visits routine clinical visits. Participants were followed-up during visits for HIV-related care 
every 1–3 months, until one year of follow-up was attained.
Participants receiving IPT also underwent safety monitoring by study nurses to track 
potential adverse reactions per local guidelines 14. Before initiating IPT, participants 
received counseling regarding the potential side effects, and were advised to seek treatment 
immediately if they experienced any of those symptoms. Individuals reporting symptoms of 
hepatotoxicity underwent blood draws to test bilirubin and transaminase levels.
Participants completed a demographic and clinical history questionnaire at baseline, as well 
as at each follow-up visit. Questionnaires were completed by study staff, and included 
questions about TB symptoms, possible IPT-related adverse events, ART status, pregnancy, 
and the number of isoniazid pills dispensed to date. The presence of TB symptoms was 
assessed at enrollment and at each subsequent follow-up visit.
Statistical Methods
Our primary outcome was completion of IPT, which was defined as receipt of ≥ 150 doses of 
isoniazid. Non-completion was defined receiving <150 doses of IPT. We examined 
univariate associations with IPT completion using chi-square or Fisher’s exact tests for 
dichotomous exposures, and Wilcoxon-Mann-Whitney tests for continuous exposures. We 
constructed a multilevel logistic regression model to explore the relationship between IPT 
completion and individual- and clinic-level predictors including concomitant receipt of ART, 
age, pregnancy status, IPT side-effects, and alcohol use. Concomitant ART exposure was 
defined as any self-reported receipt of ART drugs beginning either before, or within 7 days 
after, IPT initiation. We incorporated a random intercept to account for clustering at the 
clinic level. Variables that reached a significance of p<0.1 in the univariate analysis, or that 
were considered to be of epidemiological significance a priori, were included in the 
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multivariate model. Variables in the model were checked for co-linearity using variation 
inflation factors, and evaluated for interaction. Additionally, we performed a time-to-
treatment-discontinuation survival analysis, stratified by key exposure variables identified in 
the analysis above. Time to treatment-discontinuation was defined as days from IPT 
initiation to the date of the clinic visit where the participant received his/her last IPT 
dosages. All analyses were performed in Stata 12 (Stata Corp., College Station, USA).
Ethical Considerations
This study was approved by the Malawi University College of Medicine Research Ethics 
Committee and the Johns Hopkins University School of Medicine Institutional Review 
Board. All study participants provided individual written informed consent before study 
participation.
RESULTS:
A total of 1,359 participants were enrolled (Figure 1) across 8 study clinics, for an average 
of 122 participants per clinic (range: 47–199). During screening, 504 (37%) participants 
reported ≥1symptoms of TB and received microbiological testing for active TB disease. Of 
those tested, 27 (5%) had active TB and were thus ineligible for IPT. Of the 477 
symptomatic individuals testing negative for TB disease (i.e., initially ineligible for IPT), 
253 (53%) returned for subsequent IPT eligibility screening. Altogether 1,106 participants 
were screened for IPT eligibility (253 symptomatic TB-negative participants, and 853 
asymptomatic participants). Of these, 95 (9%) failed to meet the IPT eligibility criteria, and 
984 (89%) were started on preventive therapy by the pre-specified analysis close date. Only 
one IPT-eligible individual in our study refused to initiate preventive therapy. Ten 
participants were subsequently excluded from analysis because they were missing IPT 
outcome data.
Participants in our study were majority female (n=650, 67%) and had a median age of 33 
(interquartile range [IQR]: 27–40). Male participants were significantly older than their 
female counterparts (38.1 vs. 32.4 years, p<0.001). Most participants reported being in 
“Good” or “Fair” health at enrollment (n=788, 81%), and were classified as WHO HIV 
Stage I or II (n=794, 82%) at the time of their HIV diagnosis (Table 1). Individuals in our 
sample completed a median of 6 (IQR: 4–7) routine clinical follow-up visits during the study 
period. Concomitant ART and IPT initiation was relatively uncommon in our cohort (n=152, 
16%), though the majority of participants reported initiating ART at some point during the 
IPT treatment period (n=670, 69%).
The majority of participants initiating IPT completed treatment (n=732/974, 75%). Most 
non-completers stopped IPT due to treatment cessation/failure to return for follow-up 
(n=198, 82%). Individuals completing IPT received a median of 177 doses (IQR: 167–200), 
while non-completers received a median of 58 doses (IQR: 28–139). Compared to non-
completers, those who completed IPT were older (median age 34 vs. 31 years, p<0.001), had 
attended more follow-up visits (median 6 vs. 1, p<0.001), and were less likely to have 
experienced a prolonged treatment interruption prior to ending therapy (7% vs. 13%, 
p=0.01). Rates of completion were highest among non-pregnant women above the age of 25 
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(82%, 95% CI: 78–86%), and lowest among young women, whether pregnant (64%, 95% 
CI: 54–74%) or not (63%, 95% CI: 53–73%) (Figure 2).
Multilevel Model & Survival Analysis
After multivariate adjustment, age less than 25 (compared to age >45, aOR: 0.33, 95% CI: 
0.18–0.60) and male sex (compared to non-pregnant females: aOR: 0.57, 95% CI: 0.37–
0.88) were significantly associated with worse IPT completion rates. Each five-year increase 
in age was associated with 1.3 times greater odds of IPT completion among women 
(p<0.001) compared to only 1.1 times the odds (p=0.107) among men on univariate analysis, 
but this age-sex interaction was not statistically significant in our multivariate model 
(p>0.05, data not shown). Concomitant exposure to ART, self-reported alcohol use, being a 
current or former smoker, or reporting any TB symptoms at baseline were not significantly 
associated with IPT completion in our model. Survival analysis of time-to-IPT-
discontinuation illustrates the higher probability of treatment non-completion among 
participants younger than 25 years of age compared to their older counterparts (Figure 3), a 
difference that was statistically significant (Log-rank test p-value: 0.001).
DISCUSSION:
We found high rates of IPT completion in this cohort of adults newly diagnosed with HIV in 
rural Malawi. Our results indicate that IPT completion among newly diagnosed HIV patients 
can be reasonably high under operational conditions in rural, low-income settings. Given 
that over 99% of the IPT-eligible participants in our study initiated preventive therapy, it 
appears that IPT eligibility screening at the time of an initial HIV diagnosis was acceptable 
to patients. In our study population, older non-pregnant women had the highest odds of IPT 
completion. While concomitant receipt of ART was not significantly associated with 
increased odds of IPT completion, most of our study participants did initiate ART during the 
preventive treatment period. Our findings suggest that point-of-HIV-diagnosis TB screening 
and IPT initiation may be an effective strategy to reduce the TB burden in individuals newly 
diagnosed with HIV, especially in the high-risk period immediately preceding and following 
ART initiation.
Our findings are supported by other findings from the published literature. Earlier studies 
conducted in high TB/HIV burden settings 15–19 have found similarly high rates of IPT 
completion. A previous meta-analysis on interventions to improve IPT adherence also 
suggests that TB/HIV integration may boost IPT completion rates 20. These findings support 
the conclusion that the initial HIV diagnosis represents an opportunity to screen HIV-
infected individuals for TB, to initiate IPT for those who are eligible, and to further integrate 
HIV/TB programs.
While overall IPT completion was high in our study, several sub-groups had significantly 
lower rates. We found that individuals (especially pregnant women) who were less than 25 
years old were significantly less likely to complete IPT than their older counterparts. 
Previous work from Tanzania 18 and Uganda 21 also found that younger age was associated 
with an increased risk of treatment non-completion among HIV-infected individuals on IPT. 
Younger participants in our study tended to be healthier at baseline, and were less likely to 
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have initiated ART during follow-up, potentially making it harder to adhere to IPT without 
the support of ongoing clinic visits to obtain antiretroviral drugs. Younger individuals who 
returned for at least one clinic visit after initiating preventive therapy had IPT completion 
rates similar to their older counterparts. Interventions designed to decrease early drop-out, 
and which address the particular barriers to treatment adherence among younger patients, are 
needed to prevent non-completion in this group.
While the IPT completion rates among pregnant women observed in this study were similar 
to rates observed in other studies conducted in low-resource settings 22, compared to their 
non-pregnant counterparts, women diagnosed with HIV through antenatal care still had 
decreased odds of IPT completion (though this did not reach statistical significance after 
adjustment). WHO guidelines for the treatment of tuberculosis recommend the integration of 
TB prevention and treatment into existing antenatal care and prevention of mother-to-child 
HIV transmission programs 23. However, integration remains a challenge in many settings, 
and low rates of IPT initiation among pregnant women still persist 24,25, again highlighting 
the need for adherence interventions tailored to this group.
Compared to non-pregnant women, men also had significantly lower rates of IPT completion 
in our analysis. Numerous studies on HIV diagnosis and treatment in sub-Saharan Africa 
have noted men’s lower uptake of health-facility-based services [24] (and resulting poorer 
health outcomes 26), due at least in part on gender norms and difficulty visiting a clinic 
during working hours 27. These findings are supported by the significantly older age and 
worse general health reported by men in our study, which may reflect later initial HIV 
diagnoses. In addition to efforts to diagnose HIV-infected men earlier in the disease course, 
HIV and TB-related health outcomes for men may be improved by strategies such as 
community-based delivery of IPT, which could reduce barriers to preventive treatment 
adherence and boost completion rates in this part of the population.
As with any observational study, this research has limitations. Measurement of IPT 
completion status was based on the number of IPT doses dispensed during routine study 
visits rather than any objective measure (e.g., urine metabolites). Nevertheless, self-reported 
and/or pill count adherence correlates reasonably well with other measures of adherence 
28–30
, and from a pragmatic perspective, it is unlikely that adherence will be measured in any 
other fashion in the field. While we captured the variables that are most likely to be 
programmatically accessible, we were unable to measure all potential predictors of 
adherence, including clinic-level variables that might have exerted strong influence. We were 
also unable to comprehensively capture outcomes, including IPT-related adverse events, 
among participants who were lost to follow up. Future research could more fully evaluate a 
wider range of associations with IPT adherence, and could also consider study of potential 
interventions to improve adherence in those at greatest risk of non-completion. Additional 
studies should also consider the impact and cost-effectiveness of concurrent IPT and ART 
initiation as test-and-start continues to be scaled-up globally.
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Figure 1: 
Screening and IPT Initiation, * 224 individuals who had TB symptoms at enrollment and 
received microbiological testing for TB disease were not able to be screened for IPT 
eligibility, either because their TB symptoms did not resolve, or they did not present for 
additional follow-up
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Figure 2: 
IPT Completion Rates by Age Category and Sex/Pregnancy Status, Error bars indicate 95% 
Confidence Intervals around estimates. Isoniazid Preventive Therapy (IPT) completion was 
higher in the older age category, and lowest among young women, regardless of pregnancy 
status.
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Figure 3: 
IPT Non-Completion Survival Curve, Time to non-completion of Isoniazid Preventive 
Therapy Stratified by Age, Shown are the Kaplan-Meier curves describing the time from IPT 
initiation to the date at which the participant either completed IPT (received the last dose), or 
was censored (due to treatment default, death , refusal of further treatment, IPT stopped by 
doctor, side effects, TB diagnosis, or transfer out of the clinic area), according to whether 
participants were older or younger than 25 years of age.
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Table 1:
Patient-level clinical and demographic characteristics, by IPT completion status
Baseline Variables
Completed
IPT (N=732)
Did Not Complete
IPT (N=242)
Total
(N=974) P-value
N (%) N (%) N (%)
Age Category
18–25 132 (18.0) 72 (29.8) 204 (20.9)
0.001
26–35 296 (40.4) 87 (36.0) 383 (39.3)
36–45 204 (27.9) 58 (24.0) 262 (26.9)
>45 100 (13.7) 25 (10.3) 125 (12.8)
Sex/Pregnancy Status
Pregnant female 151 (20.6) 60 (28.4) 211 (21.7)
0.133Non-pregnant female 343 (46.9) 96 (39.7) 439 (45.1)
Male 238 (32.5) 86 (35.5) 324 (33.3)
Self-Reported Health
Excellent 100 (13.7) 31 (12.8) 131 (13.5)
0.827
Good 368 (50.3) 125 (51.7) 493 (50.6)
Fair 225 (30.7) 70 (28.9) 295 (30.3)
Poor 39 (5.3) 16 (6.6) 55 (5.7)
WHO HIV Stage*
1 or 2 599 (82.4) 195 (81.3) 794 (82.1)
0.689
3 or 4 128 (17.6) 45 (18.8) 173 (17.9)
Previous History of TB 10 (1.4) 3 (1.2) 13 (1.3) 1.0‡
Any TB Symptoms at Enrollment 164 (22.4) 40 (16.5) 204 (20.9) 0.052
Concurrent ART Exposure 122 (16.7) 30 (12.4) 152 (15.6) 0.113
Eligible for ART at Enrollment 355 (48.8) 117 (48.8) 472 (48.8) 0.983
Number of Follow-Up Visits (Median, IQR) 6 (5–7) 1 (0–3) 6 (4–7) <0.001
Experienced IPT Side-Effects during Follow-Up 6 (0.8) 3 (1.7) 9 (1.0) 0.389‡
Hospitalized during Follow-Up 36 (4.9) 7 (3.9) 43 (4.7) 0.696‡
Experienced an IPT interruption of >2 months 52 (7.1) 30 (12.5) 82 (8.4) 0.010
Current/Former Smoker 112 (15.3) 42 (17.4) 154 (15.8) 0.448
Any Alcohol Use 147 (20.1) 57 (23.6) 204 (20.9) 0.250
†
P-value obtained from a two sample Wilcoxon rank-sum test
‡
P-value obtained from a Fisher’s exact test
*7 individuals were missing WHO stage classification
**5 individuals were missing ART eligibility because of missing CD4 cell counts and missing WHO stage
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Table 2:
Univariate and Multivariate Models for IPT Completion*
Baseline Variables Unadjusted Adjusted**
OR 95% CI aOR 95% CI
Age Category
18–25 0.37 (0.21–0.64) 0.33 (0.18–0.60)
26–35 0.80 (0.48–1.35) 0.78 (0.46–1.33)
36–45 0.84 (0.49–1.45) 0.85 (0.49–1.47)
>45 Ref Ref Ref Ref
Sex/Pregnancy Status
Female, not pregnant Ref Ref Ref Ref
Female, pregnant 0.66 (0.44–0.98) 0.86 (0.56–1.31)
Male 0.69 (0.49–0.99) 0.57 (0.37–0.88)
Any TB Symptoms at Enrollment 1.25 (0.82–1.89) 1.09 (0.55–2.19)
Concurrent ART Exposure 1.27 (0.80–2.00) 1.08 (0.70–1.72)
Any Alcohol Use 0.96 (0.67–1.39) 1.09 (0.70–1.72)
Current/Former Smoker 0.90 (0.60–1.36) 1.01 (0.62–1.63)
*
Multilevel logistic models of IPT completion with clinic-level random intercept
**
Model adjusted for age (over/under 25 years), sex/pregnancy status, the presence of TB symptoms at enrollment, concurrent ART exposure, any 
alcohol use, and current/former smoking status.
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